drugset / Trial / NCT03616587
Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.
RandomizedSequentialOpen-labelTreatment
Summary
A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Women with ER Positive, HER2 Negative Advanced Breast Cancer (SERENA-1)
Timeline
- Start
- 2018-10-11
- Primary completion
- 2024-09-16
- Completion
- 2027-06-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | — | — |
| Subject | Anastrozole | Other / unclassified | — | — |
| Subject | Camizestrant | Other / unclassified | — | — |
| Subject | Capivasertib | Small molecule | — | — |
| Subject | Everolimus | Small molecule | — | — |
| Subject | Palbociclib | Small molecule | — | — |
| Subject | Ribociclib | Small molecule | — | — |